521 - Zuma-25: A Phase 2 Study of Brexucabtagene Autoleucel (KTE-X19) Chimeric Antigen Receptor T-Cell Therapy in Adult Patients with Relapsed/Refractory Rare B-Cell Malignancies

Autor: Eichhorst, Barbara, Dunleavy, Kieron, Tiacci, Enrico, Buske, Christian, Jain, Nitin, Castillo, Jorge J., Rossi, Davide, Woolven, Kate, Masouleh, Behzad Kharabi, Peng, Weimin, Schuberth, Petra C., Domper, Neus, Wolthers, Benjamin O., Palomba, M. Lia
Zdroj: In Transplantation and Cellular Therapy February 2023 29(2) Supplement:S390-S391
Databáze: ScienceDirect
Externí odkaz: